Blood cancers

‘Compelling’ results for ibrutinib in CLL

The results of a phase 3 study pave the way for the use of ibrutinib as front-line therapy in patients with chronic lymphocytic leukaemia, experts say. The RESONATE-2 study presented at the 2015 ASH Annual Meeting this week found ibrutinib (Imbruvica) reduced the risk of death by 84% compared to chlorambucil in treatment-naïve elderly patients ...

Already a member?

Login to keep reading.

© 2021 the limbic